X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ASTRAZENECA PHARMA with Unichem Lab - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs UNICHEM LAB - Comparison Results

ASTRAZENECA PHARMA    Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA UNICHEM LAB ASTRAZENECA PHARMA/
UNICHEM LAB
 
P/E (TTM) x 133.5 -287.4 - View Chart
P/BV x 20.3 2.1 956.5% View Chart
Dividend Yield % 0.0 1.2 -  

Financials

 ASTRAZENECA PHARMA   UNICHEM LAB
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-14
UNICHEM LAB
Mar-17
ASTRAZENECA PHARMA/
UNICHEM LAB
5-Yr Chart
Click to enlarge
High Rs1,285320 401.7%   
Low Rs634221 286.9%   
Sales per share (Unadj.) Rs189.6167.2 113.4%  
Earnings per share (Unadj.) Rs-0.212.0 -1.7%  
Cash flow per share (Unadj.) Rs3.816.9 22.7%  
Dividends per share (Unadj.) Rs03.00 0.0%  
Dividend yield (eoy) %01.1 0.0%  
Book value per share (Unadj.) Rs68.6117.0 58.6%  
Shares outstanding (eoy) m25.0090.88 27.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.11.6 312.9%   
Avg P/E ratio x-4,712.722.6 -20,838.3%  
P/CF ratio (eoy) x249.616.0 1,562.4%  
Price / Book Value ratio x14.02.3 604.9%  
Dividend payout %025.1 0.0%   
Avg Mkt Cap Rs m23,98824,578 97.6%   
No. of employees `0001.65.2 30.0%   
Total wages/salary Rs m1,6052,487 64.5%   
Avg. sales/employee Rs Th3,040.22,928.3 103.8%   
Avg. wages/employee Rs Th1,029.2479.4 214.7%   
Avg. net profit/employee Rs Th-3.3209.4 -1.6%   
INCOME DATA
Net Sales Rs m4,74015,195 31.2%  
Other income Rs m92110 83.6%   
Total revenues Rs m4,83215,305 31.6%   
Gross profit Rs m-1301,788 -7.3%  
Depreciation Rs m101452 22.4%   
Interest Rs m034 0.0%   
Profit before tax Rs m-1391,413 -9.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m1390-   
Tax Rs m5326 1.6%   
Profit after tax Rs m-51,087 -0.5%  
Gross profit margin %-2.711.8 -23.3%  
Effective tax rate %-3.723.1 -15.9%   
Net profit margin %-0.17.2 -1.5%  
BALANCE SHEET DATA
Current assets Rs m2,7266,426 42.4%   
Current liabilities Rs m2,4353,917 62.2%   
Net working cap to sales %6.116.5 37.2%  
Current ratio x1.11.6 68.3%  
Inventory Days Days7468 109.0%  
Debtors Days Days4177 52.9%  
Net fixed assets Rs m1,0357,410 14.0%   
Share capital Rs m50182 27.5%   
"Free" reserves Rs m94210,454 9.0%   
Net worth Rs m1,71610,636 16.1%   
Long term debt Rs m04 0.0%   
Total assets Rs m4,15615,258 27.2%  
Interest coverage xNM42.9-  
Debt to equity ratio x00 0.0%  
Sales to assets ratio x1.11.0 114.5%   
Return on assets %-0.17.3 -1.7%  
Return on equity %-0.310.2 -2.9%  
Return on capital %013.6 0.0%  
Exports to sales %5.724.1 23.6%   
Imports to sales %6.54.9 130.7%   
Exports (fob) Rs m2703,666 7.4%   
Imports (cif) Rs m306752 40.8%   
Fx inflow Rs m3755,298 7.1%   
Fx outflow Rs m4700-   
Net fx Rs m-965,298 -1.8%   
CASH FLOW
From Operations Rs m-8683 -1.2%  
From Investments Rs m-146-1,316 11.1%  
From Financial Activity Rs m862592 145.6%  
Net Cashflow Rs m709-40 -1,775.7%  

Share Holding

Indian Promoters % 0.0 50.1 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 0.3 15.1 2.0%  
FIIs % 15.7 3.0 523.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 31.7 28.7%  
Shareholders   12,856 20,176 63.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   BIOCON LTD  WOCKHARDT LTD.  AUROBINDO PHARMA  PLETHICO PHARMA  GLENMARK PHARMA  

Compare ASTRAZENECA PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Day in Green; Metal Stocks Top Gainers(Closing)

After opening the day in green, share markets in India witnessed positive trading activity throughout the day and ended the day on a positive note.

Related Views on News

UNICHEM LAB Announces Quarterly Results (4QFY18); Net Profit Down 91.1%

Jun 14, 2018 | Updated on Jun 14, 2018

For the quarter ended March 2018, UNICHEM LAB has posted a net profit of Rs 28 m (down 91.1% YoY). Sales on the other hand came in at Rs 2 bn (down 40.4% YoY). Read on for a complete analysis of UNICHEM LAB's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Jun 20, 2018 (Close)

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 8-QTR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS